Tagged with BIO

Hungary Hungary’s medicinal biotech companies are clustered in the country’s four major university towns: Budapest, Debrecen, Szeged and Pécs, with the majority basing themselves in the capital, Budapest. Click here to read more articles and interviews from Hungary

Pharma Singapore, though conscious of its limitations, has been able to leverage its key assets of location, infrastructure and local talent in order to become the business hub for the entire region, with pharma and biotech as key components in its success. Singapore is … an attractive investment destination, especially for the…

Pharma With nearly €4 billion of capital investment in large molecule manufacturing underway, Ireland’s strategy to become a premier destination for biologics FDI has proven to be successful, according to BioPharmaChem Ireland director Matt Moran. Yet, Ireland today is much more than a manufacturing hub, and is well on its way to…

Biotech The chairman of BioSingapore, Dr. Siew Hwa Ong, discusses the opportunities and challenges facing biotech SMEs in Singapore, government efforts to enhance the business environment for these SMEs, and facilitating more collaboration between companies as the most prominent pathway for future development. Could you please introduce yourself to our international…

Pharma The executive director of A*STAR’s Biomedical Research Council, Dr. Benjamin Seet highlights several remarkable milestones that the organization has been able to achieve since its inception, while underscoring how cultivating deep levels of expertise will carry Singapore’s biomedical sciences sector into its next phase of development. In a few words,…

Pharma Switzerland’s pharma industry is moving beyond staid conservatism and embracing risk in order to compete internationally and foster a new culture of innovation. Switzerland is frequently considered one of the most entrepreneurial and competitive countries in the world. As Thomas Cunei, secretary general of Interpharma, the association that represents 92…

Pharma Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring more life-changing innovation to patients. Could you please provide our readers with a general overview of the Institute of Biomedical…

Pharma Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de Elizalde reveals the key pillars that will drive the affiliate to new heights. In Mexico, generics make up 79 percent…

Pharma Founded in 2011, APC has grown to be the largest process development company in Ireland. It is the largest employer of PhD Chemical Engineers nationally, is partners with the largest pharma and biotech companies globally, and over 80% of the company’s revenue is export driven. Since starting APC in 2011, what have been…

Pharma FDI into Irish pharma has almost exclusively targeted in biologics production over the last few years, largely due to Ireland’s skilled workforce of bioprocessing technicians. NIBRT director Dominic Carolan discusses how the institute supports the Irish biopharma industry through training and recruitment solutions, while pursuing research that may help to…

Pharma Since gaining independence in 1965, Singapore has invested heavily in moving beyond being a mere supplier of low cost labor like many of its Asian neighbors and pivoting into a more knowledge-based and innovation-intensive economy. Chemicals, engineering, and electronics have always served as key manufacturing segments, but only starting from…

Pharma Merck Czech Republic’s MD reveals his plan to double Merck operations within the next five years and talks about the impact of the recent acquisition of Sigma Aldrich on the Czech Republic. You’ve assumed position as Managing Director Merck Czech Republic just over one year ago; what was the strategy…